Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3011 Added Prognostic Value of Molecular Imaging Biomarkers over Proliferation Index in Typical Lung Carcinoid: An FDG PET and SSTR Imaging Study

Introduction: Typical lung carcinoids(TCs)are rare tumors with good,although heterogeneous,prognosis.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Briganti V

Authors: Briganti V, Berti V, Abenavoli E, Linguanti F, Ciaccio A,

Keywords: typical lung carcinoid, FDG PET, SSTR imaging, MTV, TLG,

#2182 Favourable Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) for Treatment of Metastatic Rectal Neuroendocrine Neoplasia (NEN)

Introduction: Metastatic disease from rectal NEN are less common than other NEN origins, and carries a poor prognosis. Treatment evidence for such patients (pts) is lacking.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Kong G

Authors: Kong G, Grozinsky-Glasberg S, Akhurst T, Hofman M, Meirovitz A,

Keywords: PRRT, Lu-177, metastatic, Rectal, Neuroendocrine neoplasm,

#1909 68Ga-DOTA-TOC and 18F-FDG-PET/CT in the Follow-up of NET Patients treated with First Full PRRT

Introduction: Only few studies have correlated 18F-FDG and SSTR imaging with NET grade.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Rodrigues M, Nilica B, Waitz D, Stevanovic V, Uprimny C,

Keywords: 68Ga-PET, FDG,

#1790 Lanreotide Autogel/Depot (LAN) in Lung Neuroendocrine Tumours (NETs): The Randomized, Double-Blind, Placebo (PBO)-Controlled, International Phase 3 SPINET Study

Introduction: Treatment options for advanced lung NETs are limited. The phase 3 CLARINET study demonstrated antitumour efficacy of somatostatin analogue (SSA) LAN 120mg vs PBO for metastatic gastroenteropancreatic grade 1/2 (Ki-67

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Reidy-Lagunes D, Kulke M, Wolin E, Singh S, Ferone D,

Keywords: Lung NETs, lanreotide,